Literature DB >> 12693888

Update on Parkinson disease.

Andrew Siderowf1, Matthew Stern.   

Abstract

This Update reviews developments in the pathophysiology and treatment of Parkinson disease during the past several years. In the area of pathophysiology, studies have addressed the contribution of environmental factors such as caffeine and pesticides. Large-scale epidemiologic studies have also expanded the role genetic factors are thought to play. Detailed studies of kindreds with familial Parkinson disease due to alpha-synuclein and parkin have catalyzed basic science investigations into the pathologic mechanisms of the disease. These studies have led to the development of a pathophysiologic model of Parkinson disease that emphasizes abnormal protein aggregation. Studies of treatment have clarified the relative roles of l-dopa and dopamine agonists in early Parkinson disease and shown the potential for surgical interventions, particularly deep-brain stimulation, to relieve the symptoms of advanced, medically refractory disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12693888     DOI: 10.7326/0003-4819-138-8-200304150-00013

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  34 in total

Review 1.  Establishing a framework for neuropathological correlates and glymphatic system functioning in Parkinson's disease.

Authors:  Saranya Sundaram; Rachel L Hughes; Eric Peterson; Eva M Müller-Oehring; Helen M Brontë-Stewart; Kathleen L Poston; Afik Faerman; Chloe Bhowmick; Tilman Schulte
Journal:  Neurosci Biobehav Rev       Date:  2019-05-24       Impact factor: 8.989

2.  Structural reorganization of alpha-synuclein at low pH observed by NMR and REMD simulations.

Authors:  Kuen-Phon Wu; Daniel S Weinstock; Chitra Narayanan; Ronald M Levy; Jean Baum
Journal:  J Mol Biol       Date:  2009-07-01       Impact factor: 5.469

Review 3.  Oxidative and inflammatory pathways in Parkinson's disease.

Authors:  Rebecca L Miller; Marilyn James-Kracke; Grace Y Sun; Albert Y Sun
Journal:  Neurochem Res       Date:  2008-03-25       Impact factor: 3.996

4.  Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV α-Synuclein Rat Model of Parkinson's Disease.

Authors:  Qing He; James B Koprich; Ying Wang; Wen-bo Yu; Bao-guo Xiao; Jonathan M Brotchie; Jian Wang
Journal:  Mol Neurobiol       Date:  2015-05-14       Impact factor: 5.590

Review 5.  Insights into the Molecular Mechanisms of Alzheimer's and Parkinson's Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology.

Authors:  Orkid Coskuner-Weber; Vladimir N Uversky
Journal:  Int J Mol Sci       Date:  2018-01-24       Impact factor: 5.923

6.  Construction and functional activity of a recombinant vector expressing rat glutamic acid decarboxylase 65.

Authors:  Jian-Sheng Liu; Qian Wang; Ji-Bo Zhang; Ling-Ju Kong; Su-Yan Yao; De-Yu Zheng; Qun-Yuan Xu
Journal:  Neurosci Bull       Date:  2011-12       Impact factor: 5.203

7.  Genotyping Parkinson disease-associated mitochondrial polymorphisms.

Authors:  Yiguo Jiang; Tammy Ellis; Anne R Greenlee
Journal:  Clin Med Res       Date:  2004-05

Review 8.  Non-human primate models of PD to test novel therapies.

Authors:  Marc Morissette; Thérèse Di Paolo
Journal:  J Neural Transm (Vienna)       Date:  2017-04-08       Impact factor: 3.575

9.  Iron Chelators as Potential Therapeutic Agents for Parkinson's Disease.

Authors:  Carlos A Perez; Yong Tong; Maolin Guo
Journal:  Curr Bioact Compd       Date:  2008-10-01

10.  Development of a Highly Potent D2/D3 Agonist and a Partial Agonist from Structure-Activity Relationship Study of N(6)-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N(6)-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine Analogues: Implication in the Treatment of Parkinson's Disease.

Authors:  Banibrata Das; Seenuvasan Vedachalam; Dan Luo; Tamara Antonio; Maarten E A Reith; Aloke K Dutta
Journal:  J Med Chem       Date:  2015-11-30       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.